Navigation Links
EUCODIS Bioscience Appoints Bhupinder Hundle to Senior Vice President Marketing & Sales
Date:10/12/2009

VIENNA, Austria, October 12 /PRNewswire/ -- EUCODIS Bioscience, a company developing, customizing, manufacturing, and marketing enzymes for the chemical industry, announced today that it has appointed Bhupinder Hundle, PhD, to the newly created position of Senior Vice President Marketing & Sales. Dr. Hundle will be responsible for the worldwide sales of EUCODIS Bioscience' products. In 2009 the Company has started bringing to market its own enzymes portfolio. The Company had previously established its technology and its enzyme development expertise in commercial collaborations with industry partners.

"We are excited about the wealth of experience that Bhupinder brings on board in establishing and leading an effective sales force", said Rudy Pandjaitan, PhD, CEO of EUCODIS Bioscience. "At EUCODIS Bioscience Bhupinder will be responsible for building the sales structure that optimally serves our target industries in Europe, the US, and Asia."

"I am proud to join a biotechnology company like EUCODIS Bioscience, with its proven capabilities in developing and bringing industrial enzymes to the market", commented Dr. Bhupinder Hundle. "With its industry experience and its powerful technology, EUCODIS Bioscience has the potential to become a key enabler of white biotechnology applications, both in established industries and in future technologies such as the generation of fine chemicals from biomass."

Dr. Hundle comes to EUCODIS Bioscience from Lonza, Switzerland, where he headed the sales team for the Lonza Cell Discovery product range in UK, Ireland, the Netherlands, and Northern Europe. Prior to joining Lonza Bhupinder served as European Sales Director for Amaxa AG for 6 years. He has more than 10 years of experience in working with B2B customers in the pharmaceutical and biotechnology industries in Europe and the US.

Dr. Hundle has a B.Sc. (Hons) degree in Molecular Biology, an M.Sc. degree in Medicinal Chemistry from Loughborough University, UK, and received his PhD degree in Biochemistry from Simon Fraser University, British Columbia, Canada. He worked as a postdoctoral fellow at Chemical Biodynamics Laboratory, Chemistry Department, University of California, Berkeley and as a Senior Research Fellow at University of California, San Francisco.

About EUCODIS Bioscience

EUCODIS Bioscience GmbH develops, customizes, manufactures, and markets industrial enzymes.

EUCODIS Bioscience' products help customers in the chemical, pharmaceutical, and food and feed industries to make manufacturing processes more efficient and cleaner, and to generate products with superior properties.

EUCODIS Bioscience originally focused on developing enzymes for industrial partners, including GlaxoSmithKline, Henkel, and Lohmann Animal Health. Since 2009, the Company also markets its own products.

Led by an experienced management team, EUCODIS Bioscience is backed by Austrian and German institutional venture capital funds, founders, and private investors. The Company is headquartered in Austria, Europe, with subsidiaries in France and Germany.

    For more information, please visit http://www.eucodisbioscience.com

    Company contact EUCODIS Bioscience:
    Rudy Pandjaitan, PhD
    CEO
    EUCODIS Bioscience
    Campus Vienna Biocenter II
    Viehmarktgasse 2 a/ 2 OG
    A-1030 Vienna
    AUSTRIA
    +43-1-8900804
    office@eucodisbioscience.com

    Media contact EUCODIS Bioscience:
    Frank Butschbacher
    Investor Relations & Communications
    http://www.butschbacher.net
    +43-650-7844940
    office@butschbacher.net

SOURCE EUCODIS Bioscience


'/>"/>
SOURCE EUCODIS Bioscience
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. EUCODIS Bioscience Achieves Development Milestone in Second Collaboration With Lohmann Animal Health
2. Sangamo BioSciences Announces Research Collaboration With UCLA in Human Stem Cells Selected to Receive Clinical Research Award
3. Sangamo BioSciences Announces Plans to Initiate a Second Clinical Trial of CCR5-ZFP Therapeutic to Treat HIV/AIDS
4. Signum Biosciences Awarded Phase II SBIR Grant by the NIH for the Treatment of Rosacea
5. Regado Biosciences Releases Positive Phase 2a Data for the Reversible Anticoagulant System REG1 at the European Society of Cardiology Congress In Barcelona, Spain
6. Sangamo BioSciences Announces Achievement of Key Milestone in Cell Engineering Agreement With Genentech
7. Neurocrine Biosciences Presents Elagolix Data
8. Chipscreen and HUYA Bioscience to Present Clinical Data on Novel HDAC Inhibitor at the 2009 ASCO Annual Meeting
9. CMC ICOS Biologics and Implicit Bioscience Ltd Announce IC14 Antibody Manufacturing Agreement and Patent License
10. SAFC Biosciences(R) and Vivalis Collaborate to Optimize Cell Culture Media for Vaccines Production
11. ImQuest BioSciences Receives Phase I SBIR Grant to Develop a Novel Hepatitis C Virus Therapeutic Agent
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/11/2017)... 2017  True Health, a leader in integrated ... during National Breast Cancer Awareness month to educate ... Research recently published ... more than 10 million American women are at ... or BRCA2 and have not had testing. These mutations ...
(Date:10/5/2017)... Oct. 5, 2017  In response to the ... and Maxillofacial Surgeons (AAOMS) released prescribing recommendations that ... be used as a first-line therapy to manage ... Recognizing the value and ... Paper "Opioid Prescribing: Acute and Postoperative Pain Management" ...
(Date:10/2/2017)... 2, 2017  Eli Lilly and Company (NYSE: ... the third quarter of 2017 on Tuesday, October 24, ... that day with the investment community and media to ... conference call will begin at 9 a.m. Eastern time. ... live webcast of the conference call through a link ...
Breaking Medicine Technology:
(Date:10/13/2017)... ... October 13, 2017 , ... PurhealthRX , a leading ... Purzorb™ technology. Applying the Purzorb™process to full spectrum CBD oil will revolutionize the rapidly ... CBD form that can be easily incorporated into liquid products, while reducing costs to ...
(Date:10/13/2017)... , ... October 13, 2017 , ... The Visiting Nurse ... Market. Featuring a collection of specialty vendors and unique items from across the nation, ... quality-focused health and wellness services offered by the VNA. The boutique will be ...
(Date:10/13/2017)... VA (PRWEB) , ... October 13, 2017 , ... ... of DevOps and Agile Software Development, has been awarded a contract by the ... Blanket Purchase Agreement (BPA) aims to accelerate the enterprise use of Agile methodologies ...
(Date:10/12/2017)... (PRWEB) , ... October 12, 2017 , ... Planet Fitness, ... the U.S., announced today its plans to open a flagship location in Covington, LA ... the former Rooms To Go store next to Office Depot in the Holiday Square ...
(Date:10/12/2017)... (PRWEB) , ... October 12, 2017 , ... ... drug delivery system that we intend to develop to enable prevention of a ... lead to severe hearing loss, especially in pediatric patients. For cisplatin, hearing loss ...
Breaking Medicine News(10 mins):